Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma

Although TP53 co-mutation with KRAS/ATM/EGFR/STK11 have been proved to have predictive value for response to immune checkpoint inhibitors (ICIs), not all TP53 mutations are equal in this context. As the main part of TP53 mutant types, Missense and Nonsense alternations in TP53 as independent factors...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	EBioMedicine 2020-10, Vol.60, p.102990-102990, Article 102990
Hauptverfasser:	Sun, Hao, Liu, Si-Yang, Zhou, Jia-Ying, Xu, Jin-Tian, Zhang, Huang-Kai, Yan, Hong-Hong, Huan, Jiao-Jiao, Dai, Ping-Ping, Xu, Chong-Rui, Su, Jian, Guan, Yan-Fang, Yi, Xin, Yu, Rong-Shan, Zhong, Wen-Zhao, Wu, Yi-Long
Format:	Artikel
Sprache:	eng
Schlagworte:	General & Internal Medicine Immunotherapy Life Sciences & Biomedicine Lung adenocarcinoma Medicine, General & Internal Medicine, Research & Experimental Research & Experimental Medicine Research Paper Science & Technology Subtypes TP53
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!